Who are PF-07914705 Influenza saRNA's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Quadrivalent influenza modRNA vaccine, Qiv, PF-07871987 Influenza saRNA, Quadrivalent Influenza Vaccine, Assorted Licensed Hand Sanitizer Grape 01, Prepandrix™.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pf-07914705-influenza-sarna.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

PF-07914705 Influenza saRNA — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PF-07914705 Influenza saRNA (pf-07914705-influenza-sarna) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: RNA-based therapy. Area: Immunology.

marketed RNA-based therapy influenza virus Immunology Live · refreshed every 30 min

Target snapshot

PF-07914705 Influenza saRNA (pf-07914705-influenza-sarna) — Pfizer.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
PF-07914705 Influenza saRNA TARGET	pf-07914705-influenza-sarna	Pfizer	marketed	RNA-based therapy	influenza virus
Quadrivalent influenza modRNA vaccine	quadrivalent-influenza-modrna-vaccine	Pfizer	marketed	Vaccine	Influenza virus
Qiv	qiv	Pfizer	marketed	Inactivated vaccine	Influenza viruses
PF-07871987 Influenza saRNA	pf-07871987-influenza-sarna	Pfizer	marketed	RNA-based therapeutic	influenza virus
Quadrivalent Influenza Vaccine	Quadrivalent Influenza Vaccine	International Centre for Diarrhoeal Disease Research, Bangladesh	marketed	Inactivated vaccine	Influenza viruses
Assorted Licensed Hand Sanitizer Grape 01	Licensed Influenza Vaccine 3	BioNTech	marketed	Vaccine	Influenza virus hemagglutinin protein
Prepandrix™	Prepandrix™	GlaxoSmithKline	marketed	Inactivated influenza vaccine	H5N1 influenza virus surface antigens (hemagglutinin and neuraminidase)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (RNA-based therapy class)

Pfizer · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). PF-07914705 Influenza saRNA — Competitive Intelligence Brief. https://druglandscape.com/ci/pf-07914705-influenza-sarna. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab